SCHEMBL3039573

SCHEMBL3039573

Cc1ccc(N)c2c1CNC2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.43
CSF1R P07333 1/20 0.40
THRB P10828 1/20 0.37
PARP1 P09874 5/20 0.36
MAP3K9 P80192 2/20 0.36
MAP3K11 Q16584 2/20 0.36
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35
PRKCD Q05655 2/20 0.34
PRKD3 O94806 1/20 0.34
PRKCG P05129 1/20 0.34
PRKCB P05771 1/20 0.34
GLI1 P08151 1/20 0.34
GLI2 P10070 1/20 0.34
CDK4 P11802 1/20 0.34
PRKCA P17252 1/20 0.34
CTRB1 P17538 1/20 0.34
PRKACA P17612 1/20 0.34
PRKACG P22612 1/20 0.34
PRKACB P22694 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21436497 0.84 THRB (0.42) KDRCSF1RTHRBPARP1MAP3K9
SCHEMBL3044217 0.79 KDR (0.39) KDRCSF1RTHRBPARP1MAP3K9
SCHEMBL3041897 0.78 PIM1 (0.49) KDRCSF1RTHRBPARP1MAP3K9
SCHEMBL18863294 0.78 ADORA2A (0.41) KDRCSF1RTHRBPARP1MAP3K9
SCHEMBL2527674 0.78 KDR (0.38) KDRCSF1RTHRBPARP1MAP3K9
SCHEMBL3039244 0.78 PARP1 (0.36) KDRPARP1MAP3K9MAP3K11PARP10
SCHEMBL18170563 0.77 KDR (0.61) KDRCSF1RMAP3K9MAP3K11PRKCD
SCHEMBL22663482 0.75 CSF1R (0.42) KDRCSF1RPARP1MAP3K9MAP3K11
SCHEMBL22663433 0.75 CSF1R (0.46) KDRCSF1RPARP1MAP3K9MAP3K11
SCHEMBL17269693 0.74 PIM1 (0.49) KDRPARP1MAP3K9MAP3K11PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 US disclosed
WO-2022268176-A1 STEROID COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 江苏先声药业有限公司 2022-12-29 WO disclosed
EP-3738961-B1 HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF MEDSHINE DISCOVERY INC (CN) 2022-08-31 EP disclosed
US-11384065-B2 Heterocyclic compound as CSF-1R inhibitor and use thereof MEDSHINE DISCOVERY INC. (CN) 2022-07-12 US disclosed
US-20210107894-A1 HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF MEDSHINE DISCOVERY INC. (CN) 2021-04-15 US disclosed
EP-3738961-A1 HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF Medshine Discovery Inc. (CN) 2020-11-18 EP disclosed
US-7745641-B2 Nitrogen-containing heterocyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-29 US disclosed
US-20090054407-A1 Nitrogen-containing heterocyclic compound KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1880993-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054407-A1 Nitrogen-containing heterocyclic compound NR4A1, NR5A2, PRMT8 KDR 3226/4885CSF1R 1739/4885THRB 1098/4885
US-11731953-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS KDR 3104/4885CSF1R 3924/4885THRB 2094/4885
US-11384065-B2 Heterocyclic compound as CSF-1R inhibitor and use thereof CSF1R, CSF3R, IL1RN KDR 907/4885CSF1R 1/4885THRB 2338/4885
US-20210107894-A1 HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF CSF1R, CSF3R, IL1RN KDR 907/4885CSF1R 1/4885THRB 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.